Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
47 /100
MEDIUM RISK
Score updated Jul 28, 2026

IMDX — Insight Molecular Diagnostics Inc. Dilution Risk Tracker

Track IMDX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track IMDX — Get alerts when the score changes →

As of July 28, 2026, Insight Molecular Diagnostics Inc. (IMDX) has a DilutionWatch DilutionScore of 47/100, rated MEDIUM dilution risk. Insight Molecular Diagnostics Inc. has a market capitalization of $200.52M, 32.29M shares outstanding, 43 institutional holders tracked. Key dilution vectors include 819.8K outstanding warrants, approximately 12 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
40
📊 Float Risk
60
⚠️ Warrant Exposure
15
🔄Convertible Debt—

Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for IMDX.
🔔 Track IMDX — Get forecast alerts →

Market Data

Market Cap$200.52M
Shares Outstanding32.29M
Float10.08M
Cash$28.20M
Debt$1.87M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 17.4% shares (2026Q1 vs prior)
43 institutional holders · 19.61M shares
#1 BROADWOOD CAPITAL INC 11.93M shares
#2 AWM Investment Company, Inc. 2.81M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 1.07M shares
+ 17 more holders Sign up free to view →

Short Interest

Short Interest1.25M
Days to Cover4.3
% of Float12.4%
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2023-09-30
xbrl XBRL CONVERTIBLE 2017-12-31
Full SEC filing analysis available with free account →

Recent News

No recent news

What This Means for IMDX Shareholders

Insight Molecular Diagnostics Inc. (IMDX) has a DilutionScore of 47/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 28, 2026.

DilutionWatch tracks 819,767 outstanding warrants for IMDX. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: IMDX has approximately 12 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for IMDX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for IMDX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →

Understanding IMDX's Dilution Risk Factors

Primary Risk Drivers

The two highest-risk factors for Insight Molecular Diagnostics Inc. are Offering Ability and Float Risk, both scoring at moderate levels. Offering Ability at 60 indicates a strong potential for future capital raises, which could dilute existing shareholders. Float Risk at 60 suggests that the company’s share structure may be vulnerable to large increases in circulating shares, especially if new equity is issued. These factors together create a mechanism where additional shares can be issued without significant shareholder approval, directly increasing the total number of shares outstanding and reducing ownership percentage for current investors.

Factors Currently Not a Concern

Warrant Exposure is currently low at 15, indicating minimal risk from warrant exercises that could dilute shareholders. However, an increase in warrant activity or new warrant issuances would raise this score. Convertible Note Risk scores at 40, suggesting that while there are convertible notes outstanding, they do not pose an immediate threat. A significant conversion event or issuance of additional convertible debt would elevate this factor and increase dilution risk.

SEC Filings to Watch

Several filings signal potential dilution events. An S-3 registration statement could indicate plans for a large equity offering, directly increasing share count. A 424B5 filing often accompanies new equity offerings or rights issues, signaling upcoming dilutive actions. An 8-K Item 1.01 filing may report material events such as new equity issuances or changes in capital structure. Additionally, a 10-Q filing could reveal updated financials that suggest increased reliance on equity financing, which would raise Offering Ability and overall risk.

How Dilution Happens

When Offering Ability is high, the company may issue new shares through public offerings or private placements. Float Risk increases the potential for these shares to enter the market quickly, diluting existing holdings. As convertible notes convert into equity, the total number of shares outstanding rises, reducing each investor’s ownership percentage. Warrant exercises also contribute by issuing new shares upon exercise, further expanding supply and lowering per-share value.

What Would Make This Worse

A significant deterioration in risk would occur if Offering Ability and Float Risk both spike due to a planned equity offering or a large convertible note conversion. If the company begins issuing warrants or convertible notes at scale, those factors would rise rapidly. Additionally, any major capital raise through an S-3 filing followed by a 10-Q showing declining cash reserves could signal that dilution is imminent and necessary for survival, increasing overall risk.

Key Insight

While current scores are moderate, the interplay between Offering Ability and Float Risk creates a potential pathway for rapid dilution if new equity is issued or convertible instruments convert.

How to Monitor IMDX for Dilution Risk

What This Risk Level Means

For an operating company like Insight Molecular Diagnostics Inc. (IMDX), a medium dilution risk score indicates that while the company is not in immediate danger, it is at a point where strategic capital needs are being considered. As a micro-cap entity, IMDX operates with limited financial buffers and must carefully manage its equity structure to avoid over-dilution. The company’s size and stage of development make it more susceptible to dilutive actions such as equity offerings or convertible note conversions, which can significantly impact existing shareholders.

What Typically Happens Next

Companies at this profile often proceed with capital-raising activities such as shelf registrations or ATM programs to fund operations. These mechanisms allow for flexible funding while potentially increasing the outstanding share count. Additionally, warrant exercises and convertible note conversions are common occurrences that can further dilute shareholder equity. Monitoring these patterns is essential for understanding how the company's capital structure evolves over time.

Monitoring Playbook

To effectively track IMDX, use DilutionWatch to set up alerts for changes in dilution metrics and key financial indicators. Check scores weekly or bi-weekly, especially around earnings releases or SEC filing dates. When thresholds are hit—such as a sudden jump in Offering Ability or Cash Runway scores—immediately review recent filings and press releases for new equity activity. Consider using Shelf & ATM Monitor to track potential offerings that may not yet be announced but could affect share count.

Early Warning Signals

Three key warning signs include: 1) An increase in Offering Ability or Float Risk scores without a corresponding capital raise, 2) A sudden spike in convertible note activity or warrant issuance in SEC filings, and 3) A significant drop in Cash Runway score that indicates reduced cash reserves. These changes often precede dilutive actions that could negatively impact shareholder value.

What a Positive Resolution Looks Like

A positive shift in IMDX’s dilution profile would occur with a capital raise that strengthens the balance sheet, reducing reliance on dilutive financing. Paying down debt or allowing warrants to expire without exercise would also improve the risk score. Any of these actions can reduce future dilution pressure and signal improved financial health.

Watch For

Unannounced equity offerings, convertible note conversions, and warrant exercises that could increase share count unexpectedly.

Full SEC filing analysis available with free account  →
Track IMDX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking IMDX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

AAT AHRT ALOT AMPH AMPY

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for IMDX
IMDX FDA Catalyst Timeline & Biotech Grade — BiotechSignsIMDX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.